Dear Editor, Despite therapeutic milestones achieved, the optimal therapy of relapsed/refractory multiple myeloma (MM) remains controversial [1] . Treatment options have increased over the last few years, especially with the availability of novel agents for routine care and within clinical trials [2] . Lenalidomide is an oral immunomodulatory drug with significant activity in this setting and has been approved by European Medicine Agency (EMEA) in association with dexamethasone for the treatment of patients with at least one prior therapy [3] . To improve response rate and long-term outcome of relapsed/refractory MM patients, new lenalidomide combinations are investigated with promising results [4] [5] [6] . Knop et al. recently reported that Revlimid, Adriamycin and dexamethasone (RAD) association induces substantial and durable remission rate with an acceptable toxicity profile in pretreated MM patients [7] .
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However, in their schedule, Adriamycin was given as continuous infusion over 96 h, necessitating the patient's hospitalisation and sometimes a central venous catheter insertion. A modification of Knop RAD regimen, including Adriamycin as a bolus single dose, days 1 and 4, was proposed to facilitate the administration in the outpatient setting.
Between May and December 2008, 10 patients (4 M/6 F) with relapsed/refractory MM were planned to receive six 28-day cycles of RAD.
Main pre-treatment characteristics were the following: median age 69 years (range 50-78); WHO performance status 0-3; median Hb 8.95 g/dl (range 8.3-12.1); median B2M 4.4 mg/l (range 2.5-9.1); median bone marrow plasma cell infiltration 40% (range 5-80); and median time from MM diagnosis to treatment 33 months (range 11-130). All patients had received more than two chemotherapy regimens (range 1-6). Five patients were previously treated with autologous stem cell transplantation.
RAD schedule included Revlimid 25 mg days 1-21, Adriamycin 40 mg/m 2 i.v. days 1 and 4, and dexamethasone 40 mg p.o. days 1-4. Peg-filgrastim was administrated on day 6. Aspirin 100 mg/die was given as prophylaxis for thrombosis. The International Myeloma Working Group criteria were used for definition of response [8] ; toxicity was graded according to National Cancer Institute-Common Toxicity Criteria (NCI-CTC) criteria.
Of the 10 patients, two were not evaluable for response because of early withdrawal due to progression of the disease. At the end of treatment, a clinical response was observed in seven patients (four VGPR and three CR) and disease progression in one. The best response was observed after a median of 8 weeks of treatment (range 4-12) ( Table 1) .
Myelotoxicity was the primary and major side effect. Leukopaenia and thrombocytopaenia of grade 2 were observed in 5/8 patients while of grade 4 in one patient, leading to dose reduction. One patient died from infectious complication (pneumonia). Other non-haematological side effects were fever (one case), fatigue (three cases) and diarrhoea (two cases). No relevant neurological symptoms were found. After a median follow-up of 54 weeks (range 8-80), all six patients have experienced a progression of disease, requiring a new salvage therapy. Median time to progression was 16 weeks (range 12-24). In conclusion, although weakened by the small number of cases and short-lived duration, these data showed that this modified RAD is feasible, well tolerated and effective in refractory/relapsed MM, allowing the management of patients on an outpatient basis. 
